Diagnostics company Metropolis Healthcare has announced the launch of a blood test, COVIPROTECT, which helps to measure the immunity status of a person vaccinated with the Covid-19 vaccine.
The new and upgraded quantitative test helps to understand seroprevalence in a community and determine the possibility of past infection.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The highly sensitive and specific antibody assay detects IgG type of antibodies to S1 & S2 subunits of spike proteins of SARS-CoV-2.
COVIPROTECT is Conformité Européenne (CE) marked and is approved by the US Food and Drug Administration (FDA) EUA as reported by HEALTHCARERADIUS.
Metropolis Healthcare Group president Nilesh Shah said: “Metropolis has been at the forefront of Covid-19 testing across the country from day one of the pandemic. In our pursuit to offer the best possible tests for the citizens, we have launched this immunity-check test called COVIPROTECT.
“This test is not mandatory but helps people understand if they have responded to the vaccine and if they have developed enough antibodies.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe test is available across the company’s network in India. It determines the antibodies against the viral spike proteins and if a person has developed enough antibodies after vaccination.
It is recommended to take the test three to four weeks after natural infection and two weeks after the second dose of the vaccine.
Reports will be generated within 24 hours.
Metropolis is currently assisting patients and vaccinated individuals to study their antibody titre.
